SYSho Yonezawa

Sho Yonezawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sho Yonezawa has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Deep learning and digital pathology powers prediction of HCC development in steatotic liver disease

    by Takuma Nakatsuka, Ryosuke Tateishi, Masaya Sato, Natsuka Hashizume, Ami Kamada, Hiroki Nakano, Yoshinori Kabeya, Sho Yonezawa, Rie Irie, Hanako Tsujikawa, et al.

    Background and Aims: Identifying patients with steatotic liver disease who are at a high risk of developing HCC remains challenging. We present a deep learning (DL) model to predict HCC development using hematoxylin and eosin-stained whole-slide images of biopsy-proven steatotic liver disease. Approach and Results: We included 639 patients who did not develop HCC for ≥7 years after biopsy (non-HCC class) and 46 patients who developed HCC Export


  • Open Access

    A deep convolutional neural network-based algorithm for muscle biopsy diagnosis outperforms human specialists

    by Yoshinori Kabeya, Mariko Okubo, Sho Yonezawa, Hiroki Nakano, Michio Inoue, Masashi Ogasawara, Yoshihiko Saito, Jantima Tanboon, Luh Ari Indrawati, Theerawat Kumutpongpanich, et al.

    Histopathologic evaluation is essential for categorizing and studying neuromuscular disorders. However, experienced specialists and pathologists are limited, especially in underserved areas. Although new technologies, such as artificial intelligence, are expected to improve medical reach, their use in rare diseases is challenging because of the limited availability of training datasets. To address this knowledge gap, we developed an algorithm based on deep convolutional neural networks that used data from microscopic images of hematoxylin-and-eosin-stained pathology slides. Our algorithm differentiated idiopathic inflammatory myopathies (mostly treatable) from hereditary muscle diseases (mostly non-treatable) and achieved better sensitivity and specificity than real physicians' diagnoses. Furthermore, it successfully and accurately classified four subtypes of the abovementioned muscular conditions. These results suggest that our algorithm can be safely used in a clinical setting. We established the similarity between the algorithm's and physicians' predictions using visualization technology, and clarified the validity of the predictions.